Clinical Trial Update: Macugen for Histoplasmosis [NA]

View source ↗

Summary

A clinical trial evaluating Macugen (pegaptanib) for ocular histoplasmosis with choroidal neovascularization has been terminated; no results are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Ocular Histoplasmosis

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Barnes Retina Institute | Conditions: Ocular Histoplasmosis, Choroidal Neovascularization | NA | Status: TERMINATED